FAPI and Tumor Microenvironments
Relationship between the SUVmax of primary lesion on 18F-FAPI-42 PET/CT imaging and the clinicopathological characteristics of patients with gastric cancer
Fu Lilan, Xie Fei, Dong Ye, Han Yanjiang, Zhong Jinmei, Xiao Caixia, Tang Ganghua, Wu Hubing, Zhou Wenlan
Published 2023-06-25
Cite as Chin J Nucl Med Mol Imaging, 2023, 43(6): 331-336. DOI: 10.3760/cma.j.cn321828-20230314-00058
Abstract
ObjectiveTo explore the relationship between 18F-fibroblast activation protein inhibitor (FAPI)-42 SUVmax of primary gastric cancer and clinicopathological factors of patients.
MethodsFifty-one patients (31males, 20 females, age: 51(47, 65) years) with gastric cancer who underwent 18F-FAPI-42 PET/CT before surgical resection in Nanfang Hospital, Southern Medical University from February 2022 to January 2023 were analyzed retrospectively. The clinicopathological factors that might affect tumor SUVmax (including gender, age, tumor location, pathological type, histological grade, Lauren classification, vascular and(or) neural invasion, programmed cell death-ligand 1 (PD-L1) expression, pathologic(p)T stage, pN stage and pTNM stage) were evaluated by the univariate analysis (Mann-Whitney U test or Kruskal-Wallis rank sum test) and multivariate analysis (multiple linear regression analysis).
ResultsThe sensitivity of 18F-FAPI-42 PET/CT in the diagnosis of patients with primary gastric cancer was 82.35% (42/51). The diagnostic sensitivities for early gastric cancer (T1) and locally advanced gastric cancer (T2-T4) were 59.09%(13/22) and 100%(29/29), respectively. The SUVmax of primary lesion was 4.90(1.71, 12.51). The univariate analysis showed that SUVmax of primary gastric cancer was related to tumor location (z=-2.00, P=0.046), pT stage (H=36.94, P<0.001), pN stage (z=-3.89, P<0.001), pTNM stage (H=31.49, P<0.001) and vascular and(or) nerve invasion (z=-5.22, P<0.001), but not related to pathological type, histological grade, Lauren typing, and PD-L1 expression (z values: from -1.78 to -0.09, all P>0.05). pT stage was found to be a significant independent factor for SUVmax in primary gastric lesion by multivariate analysis (t=2.52, P=0.015).
ConclusionsThe 18F-FAPI-42 SUVmax of primary tumor was related to tumor location, pT stage, pN stage, pTNM stage, and vascular and(or) nerve invasion; pT stage is an independent factor affecting tumor SUVmax. The ability of 18F-FAPI-42 PET/CT to detect gastric cancer is mainly affected by pT stage.
Key words:
Stomach neoplasms; Fibroblasts; Antagonists and inhibitors; Positron-emission tomography; Tomography, X-ray computed
Contributor Information
Fu Lilan
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Xie Fei
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Dong Ye
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Han Yanjiang
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Zhong Jinmei
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Xiao Caixia
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Tang Ganghua
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Wu Hubing
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
Zhou Wenlan
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University
Guangdong Provincial Drug Administration Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou 510515, China
